Latest Information Update: 11 Aug 2011
At a glance
- Originator Norax
- Class Enzymes
- Mechanism of Action Enzyme stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Steatorrhoea
Most Recent Events
- 12 Apr 2004 Axcan and Nordmark have created a joint venture known as Norax
- 10 Mar 2003 Preclinical trials in Steatorrhoea in Canada (unspecified route)